News and Trends 2 Jul 2019 Microbiome Food Supplement Improves Metabolic Syndrome in Overweight People A food supplement made from bacteria, developed by a Belgian research group, has improved symptoms of the metabolic syndrome including insulin resistance and high blood cholesterol levels in overweight volunteers at risk of heart disease and type 2 diabetes. The metabolic syndrome is a collection of conditions including high blood cholesterol, insulin resistance and high […] July 2, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jun 2018 Danish Biotech Plans Phase II Study to Fight A Rare Eating Disorder Saniona, a biotech focused on ion channel research, plans to test its lead candidate in a Phase IIa study for the rare eating disorder hypothalamic obesity. Saniona, based in Copenhagen, plans to start a Phase IIa trial testing its product, Tesomet, a combination of tesofensine and metoprolol, in hypothalamic obesity. The study would complement the […] June 11, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 23 Aug 2017 Boehringer Ingelheim Enters the Clinic with Two New Diabetes Drugs Boehringer Ingelheim starts two new Phase I trials with drugs intended to treat type 2 diabetes and obesity discovered through a partnership with Danish biotech Zealand. The new Phase I trials initiated by Boehringer Ingelheim will be conducted in Germany, with results expected at the end of 2018. The drugs evaluated will be a long-acting […] August 23, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jul 2017 FREE White Paper! All You need to Know about Omics and Body Fat What do you think when you hear the word ‘lipid’? I bet your thoughts include fat, energy, hormones, maybe cells? But what if I told you that lipids can also be considered as biomarkers? Very important biomarkers too that can be analyzed and identified using multiparametric statistical analysis! With more and more research focusing on […] July 19, 2017 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Startup Scout 30 Jun 2017 This Danish Biotech Thinks it Can Tackle the Obesity Epidemic Apart from boasting big players in the space of metabolic diseases including Novo Nordisk and Zealand Pharma, Copenhagen is a hotspot for research on obesity and diabetes. This week we had a look at Copenhagen’s latest addition to the field, Antag Therapeutics. Mission: Antag Therapeutics is working on new treatments for the growing number of patients with obesity. […] June 30, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jun 2017 This Company Uses the Human Microbiome to Discover New Disease Mechanisms A whole new avenue to human health and disease could soon be accessible, thanks to the human tissue microbiome. Vaiomer has found a way to make it possible! Has anyone else ever been unsettled by the idea that the human body hosts about 10 times more microbes than human cells? Although this might seem an […] June 19, 2017 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 11 Apr 2017 French Microbiome Startup Gets a Series A Funding Boost to Regulate Appetite The French biotech startup TargEDys has extended its series A funding initiated in April 2016 by €3.5M to accelerate the development of its pipeline. After raising an initial €5.8M in a series A funding round from big names like Seventure Partners, TargEDys has now raked an additional €3.5M from the Zaluvida group. The company has also appointed Christoph […] April 11, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jan 2017 Antibody Treatment for Obesity and Type 2 Diabetes enters Phase II Novartis is initiating Phase II trials with an antibody licensed from German biotech MorphoSys that tackles the obesity and diabetes epidemic. MorphoSys is a billion euro biotech that develops therapeutic antibodies for big names like Bayer, Pfizer, GSK, Boehringer Ingelheim, Roche and Janssen. The company is now adding type 2 diabetes to its long list of indications; bimagrumab will start Phase […] January 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2017 Top European VC and CRO fund Young Metabolic Disease Biotech Eternygen has received €8M in a Series A round led by Epidarex Capital that will be used to advance its pipeline in collaboration with Evotec. Eternygen is a young biotech in Berlin focusing on the treatment of metabolic diseases. The company has now raised €8M in Series A, led by Scottish biotech VC Epidarex Capital. Among the […] January 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2016 New Link found between the Microbiome and “Genetic Obesity” Researchers at King’s College London have found a new link between gut microbiome diversity (or, more specifically, the lack of it) and a particularly troubling kind of obesity. This finding could also help explain the inheritability of this disease. The explosive growth of the Microbiome field promises a whole new type of therapies, but this […] October 5, 2016 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email